CJC-1295
Raises growth hormone for days; muscle and fat claims unproven.
A 30-amino-acid version of sermorelin, modified to bind a blood protein so it lasts for days. Small studies show it raises . Its only body-fat trial was halted in 2006 after a participant died. A , also called DAC:GRF and Modified GRF 1-29 (the version without DAC).
What the evidence shows
Side effects and risks
Who should avoid it: Anyone with heart disease or active cancer, and athletes.
Athletes: Prohibited at all times (class S2). Named on the list as a growth-hormone-releasing factor. An NRL player got four years for it. Wikipedia, Cronulla supplements saga
How it works
- Where it acts
- Growth-hormone-releasing hormone receptors. The DAC version binds a blood protein, so it lasts about a week.
- What it changes
- A long rise in growth hormone and IGF-1.
- What people notice
- In small studies, IGF-1 stayed raised for more than a week after one injection. Flushing and a faster heart rate were reported.
How it has been given in studies
Injected under the skin once a week or every two weeks, dosed by body weight, for two or three doses. The short-acting version sold without DAC has no published human trials.
Getting it in the United States
The legal route for CJC-1295
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding pharmacy via clinics
FDA advisers voted against adding it to the compounding list and a final rule is expected by early 2027. Lawyers warn pharmacies that compounding it now carries enforcement risk.
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Deeper sleep and better recovery, usually stacked with ipamorelin
- Slow fat loss over months
Reported problems
- Flushing and a pounding heart just after injecting
- Water retention, tingling or numb hands
- Headaches
The flushing and heart-rate reports match the adverse events FDA cites.
More contextCase reports, what public figures say, videos and articles and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Harm reportedtrial result in rare group - 1 person - 2006
A participant at an Argentine site in the 192-person phase 2 trial for HIV-related belly fat died. The company halted the study. The treating doctor reportedly blamed undetected coronary disease, but development ended as a precaution. No completed efficacy trial exists.
Source: aidsmap, 2006-07
Harm reportednews-reported case - 2026
Australia's regulator has logged reactions to injected peptides sold this way, including severe allergic reactions needing adrenaline and hospital care. The report names CJC-1295 as a commonly sold product but does not tie cases to one peptide.
FDA flags heart rate and vasodilatory reactions
Harm reportedcase series - 2023
The FDA says it identified serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. It notes that clinical data are limited.
What experts and influencers say
Paraphrased from the linked sources.
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Devoted a full episode in 2024 to how these peptides are thought to work and how people use them. He presents possible benefits for healing, growth hormone, sleep and libido, and also says most of the data comes from animals, that black-market products may be contaminated, and that anyone with a tumor or cancer concern should avoid peptides that promote growth or new blood vessels.
Source: Huberman Lab episode, 1 Apr 2024
Andrew HubermanInstagramMixed view
Has promised to end what he calls the FDA's war on peptides and has called himself a big fan. In February 2026 he said the FDA planned to move about 14 experimental peptides back to compounding pharmacies.
Robert F. Kennedy Jr.InstagramRecommends
Told listeners he sees no reason to pick CJC-1295 over approved relatives until safety questions are settled, pointing to the trial death and fluid retention.
Andrew HubermanInstagramWarns against
Judges each peptide separately. He sees no use case for BPC-157: no human evidence, animal data mostly from one lab, and claims that keep widening. He is not a proponent of growth-hormone peptides such as CJC-1295, citing short studies and no long-term safety data. He says elamipretide makes sense only for Barth syndrome, that the risks of melanotan II probably outweigh a cosmetic tan, and that he stopped prescribing bremelanotide. He regards the GLP-1 drugs as clearly effective.
Peter AttiaInstagramMixed view
Lists CJC-1295 among substances that may pose significant safety risks in compounding. It cites possible immune reactions, impurity problems and serious events such as raised heart rate and a body-wide flushing reaction.
US Food and Drug AdministrationSourceWarns against
Co-wrote a review of 565 studies on six peptides, including CJC-1295 and ipamorelin. Concluded proof of benefit is missing, safety is unknown and marketing has outrun the science, and advised waiting for rigorous trials.
Source: UCLA Health news, 2026-08
Thomas KremenWebsiteWarns against
Photo source: uclahealth.org
Co-wrote a Lancet comment calling illicit injectable peptide use among young people an emerging public health issue. Named BPC-157, CJC-1295 and retatrutide and urged curbs on influencer and affiliate marketing.
Source: The Medical Republic, 2026-05
Jason NagataSourceWarns against
Wrote that Australian wellness clinics stretch compounding rules to supply CJC-1295, and that even a pure product keeps IGF-1 raised for over a week, which he linked to cancer risk.
Christopher RudgeWebsiteWarns against
Photo source: profiles.sydney.edu.au
After the 2006 trial death he told a trade outlet that any problem would be specific to the growth hormone releasing compound, not to the company's long-acting drug technology.
Source: aidsmap, 2006-07
Mark PerrinSourceMixed view
Money: Led the company developing CJC-1295
As an Enhanced Games recruit he listed testosterone, BPC-157, CJC-1295, ipamorelin and thymosin as substances he was using in 2025.
Source: Wikipedia, Enhanced Games, 2025
James MagnussenWebsiteRecommendsSays they used it
Money: Paid Enhanced Games competitor
Photo source: abc.net.au
Told the public not to inject peptides bought online. Said unauthorized products are illegal, unproven and may cause organ damage, clots or tumour growth. A research-use-only label does not make them legal.
Source: Health Canada advisory, 2026-04
Health CanadaSourceWarns against
In August 2014 accepted a backdated 12-month doping ban over the club's 2011 peptide program, as did most other players who received show-cause notices. Missed the rest of the season and a Four Nations tournament.
Source: Wikipedia, Cronulla supplements saga, 2014
Paul GallenInstagramMixed viewSays they used it
Wrote that human evidence for BPC-157 amounts to three tiny reports. Called self-injection of online peptides high-risk, uncontrolled self-experimentation and asked for blinded placebo-controlled trials.
Stuart PhillipsWebsiteWarns against
Photo source: science.mcmaster.ca
Told readers that many online peptides are not authorized in Canada. Noted BPC-157 was tested mainly in animals. Advised checking for a Drug Identification Number.
Source: ScienceUpFirst, 2026-08
ScienceUpFirstSourceWarns against
Said he stopped the program after a few weeks once he learned players were being injected. The league still suspended him for 12 months in 2013.
Source: Wikipedia, Cronulla supplements saga, 2013
Shane FlanaganWikipediaWarns against
The NRL fined the club 1 million Australian dollars over its 2011 program, with 400,000 suspended on governance conditions. Dank admitted overseeing injections of CJC-1295 and GHRP-6.
Source: Wikipedia, Cronulla supplements saga, 2013
Cronulla-Sutherland SharksSourceWarns againstSays they used it
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
What are peptides, and are they safe? Here's what to know
Grace Abels, PolitiFact reporter
Explains what peptides are and why unapproved ones like CJC-1295, BPC-157 and Melanotan are sold online as research chemicals with little human safety data.
Plain-language fact-check of where these peptides stand
Amino-acid sequence
Position 30 carries a linker that binds albumin (DAC). Striped tiles are mirror-image (D) amino acids, which resist breakdown.
Questions people ask
What is the difference between CJC-1295 with and without DAC?
The DAC version binds a blood protein, so it lasts about a week, and in small studies IGF-1 stayed raised for more than a week after one injection. The short-acting version sold without DAC, also called modified GRF 1-29, has no published human trials.
Why is CJC-1295 stacked with ipamorelin?
Users report deeper sleep and better recovery, usually when it is stacked with ipamorelin. These are recurring forum themes, not trial results.
What are the side effects of CJC-1295?
Users report flushing and a pounding heart just after injecting, water retention, tingling or numb hands and headaches. FDA cites serious adverse events, including a faster heart rate and widened blood vessels, and a risk of immune reactions.
Did someone die in a CJC-1295 trial?
Yes. A participant in the 2006 phase 2 trial died; the treating physician attributed the death to undiagnosed heart disease, not the drug, but development ended.
Is CJC-1295 legal?
In the US it is not on the list pharmacies may compound from, and in December 2024 FDA proposed keeping every form of it out of compounding. In Australia possession without authority is illegal, and Health Canada named it in a 2025 advisory.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Teichman et al. 2006: CJC-1295 in healthy adults
- FDA: bulk substances that may present significant safety risks
- aidsmap: lipodystrophy study halted after patient death (Jul 2006)
- FDA briefing: CJC-1295 and compounding (Dec 2024)
- Finnrick: vendor test counts
Structure: PubChem